Regeneron throws struggling CytomX a lifeline with $30M cancer bispecific deal
Regeneron is teaming up with a biotech that has struggled after axing its lead program just four months ago.
The big biopharma signed a licensing deal with CytomX on Thursday morning, ponying up $30 million upfront to work together on bispecific cancer treatments. The deal comes with milestone payments that could make it worth as much as $2 billion if it hits research, development and sales benchmarks.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,800+ biopharma pros reading Endpoints daily — and it's free.